2 weeks Ago By ABMN Staff
Lifesci Capital began coverage on shares of Monte Rosa Therapeutics ( NASDAQ:GLUE – Free Report ) in a report issued on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $19.00 price objective on the stock.
Lifesci Capital also issued estimates for Monte Rosa Therapeutics’ Q4 2024 earnings at ($0.66) EPS and FY2024 earnings at ($2.00) EPS.
Separately, Wells Fargo & Company lowered Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $14.00 to $11.00 in a research note on Thursday, December 19th.
View Our Latest Research Report on GLUE Monte Rosa Therapeutics Price Performance Institutional Inflows and Outflows Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at approximately $220,000. Two Sigma Advisers LP acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $180,000.
Two Sigma Investments LP grew its holdings in shares of Monte Rosa Therapeutics by 1,965.1% in the 4th quarter. Two Sigma Investments LP now owns 278,785 shares of the company’s stock valued at $1,935,000 after buying an additional 265,285 shares during the period.
Rafferty Asset Management LLC acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $192,000. Finally, ProShare Advisors LLC acquired a new position in Monte Rosa Therapeutics in the 4th quarter worth $101,000. Institutional investors own 79.
96% of the company’s stock. Monte Rosa Therapeutics Company Profile ( Get Free Report ) Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Stories Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
